Member Info for ratcliffewriter

Grainger I have to correct you re 201. It was a phase 1/2 trial, just a toxicity and dose escalation matter. It had 12 patients and basically it didn't kill any of them. An RNS announcing the results said "...the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate."

Note the words 'has the potential' and more interestingly 'future studies' (four years on and precisely zilch progress, and nobody answering the cold calling from Val to offer so much as a brass farthing).

The RNS said they would use the results to produce research papers for Peer Reviewed Publications, of which there have been.......none. Not a word.

It also said that the data would be shared with potential industry partners, who to date number.....zero.

It is worth noting that the RNS in question celebrated its fourth birthday today, so the 'game changer blockbuster' that some would have us believe is 201 produced nothing of interest to anyone at the end of its dose escalation trial on insignificant numbers, and has attracted neither interest nor investment, nor generated any peer review work whatsoever in the subsequent four years.

I started watching this share at the height of the old board's tub-thumping activities and pondered putting money in, but everything they said seemed shallow and lacking in substance, and frankly the board changes since seem to have made no difference whatsoever as far as I can see, except that instead of small, unsuccessful early trials, no development works seems to have gone on at all. The level of interest from 'potential industry partners' remains consistent too, at nil.

Potential opportunities.....might have a fiver on Lord Lucan winning the Grand National on Shergar next year. Risky bet, but huge returns to be had.

PM - you say 'If Valirx was 20/30 million and burning only 2 million bringing in evaluation projects and selling them at the preclinical stage for many millions and huge milestone payments then dilutions would be almost nothing with huge returns.'

But it isn't is it? Val isn't at 20 or 30 million, it's burning money it can't afford, and it isn't selling anything at any stage. It's like saying that if you won the lottery you could buy a mansion. But you haven't, so you can't.

Maybe you've got a point there - John Gilchrist was presumably seduced by products called 201, 301 and 401, which the old and vilified board talked up while counting down to the next discounted placing. But of course it isn't like that now is it?

A man who believed in the long term success of Val some years ago and according to his posts ploughed over 200,000 pounds into the company (1,600 after one consolidation, 12.80p after two) who suddenly stopped posting, and if the stories were true he took his own life after the catastrophic losses. There was a crowdfunding effort for his widow to which at least one board member contributed...

Iceman - 'Play the long game and you cant lose!'

Yes you can. Ask John Gilchrist. Ask anyone who has bought and held over the last 15 years, or even held through any one of the three consolidations.

So by ' the clients of the brokers' you mean 'ordinary punters', 'suckers' and 'dreamers' do you? Because last time I looked there wasn't a single institutional investor in Valirx. Is that correct?

Uncanny - you said every placing has 'historically been filled by institutional clients 100%.'

Seriously?

Name me some of the institutional investors who have holdings in VAL?

Porky - you say some have lost 98 percent of their investment, but it's potentially a lot worse than that. To give an idea of the damaging nature of three 125 to 1 consolidations, a million pounds consolidated as things are here would now be worth under 52p, but only if the share price remained the same. If it halved after a consolidation (and it frequently did, or worse) your million quid is now about 25p. I know even the hardiest here haven't put a million in, but any smaller amount gets too many zeros after the decimal point. And the consolidations are a result of placing after placing with no commercial interest. That's not a deramp, it's a fact.

CB - very little it seems,unless they up the prices on the coffee machine at the lab and see if that can turn a profit perhaps.

On the 1st of May this year the SP was 9.25p when Iofas posted 'SP will continue to slide to the next fund raising', so perhaps a reflection of his credibility and prophetic abilities.

If you look at Ignota labs' website you'll see its headline page proclaims 'Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects.'

Not really 'emerging' I'd say, more 'bin dipping', much like VAL and the 'success story' that was VAL201.

Still, with a MOI signed, it could produce funds as fast as the LOI with TheoremRx did/will/didn't/won't.

Emptyend - absolutely correct. Especially at this stage in Scancell's development, more so than ever.

I always understood that a company is obliged to RNS (among other things) information that may have a material effect on the share price. However, even things like serious adverse effects during a trial don't get updated daily or weekly, just incorporated into results when published, and the same with ORR etc. Now if I were running a company and had a point where i wanted data released, and not ahead of a schedule, I imagine it would be perfectly in order to check and recheck any results or analysis which can take as long as a company wants, within reason. While information should be released as required, there will be ways and means of adapting a time of release I guess. I'm not in the least bit bothered if results wait until the company is ready to do so - I'd be more worried if tiny bits of good news popped out at random. Silence may yet prove golden....

Amazing how quickly a well-aimed 'ohmygodthey'regoingtodoaplacing' took hold.

Usual suspects up to the old tricks. Relax.

A lot of use of the words 'appears', 'assumes' and 'could.'

So all just optimistic guesswork then.

Be fair WTP, you're allowed to discuss and promote placings or the indubitably negative implications of results being announced early/on time/late, but anything resembling optimism on the basis of progress and comments and reasonable expectations over the last year or more are to be actively poo-pooed. Don't forget the voices who declared that Redmile and Vulpes wouldn't be holding for more than 12 months - they're all around, all presumably holding, and all on the shortlist to be Vicar of Bray.

Lindy's not the type to chicken out either. This is no shell company, no fowl practices, everyone working to advance the science and not feathering their nest.

Look like sub 2p has arrived - the price at which I was urged by some very enthusiastic posters to 'get in now, it can't go much lower', and that was before the last consolidation.

It'll be interesting to see if this helps boost the price ahead of the placing.